Why Is MODERNA INC (MRNA) Stock Up Today?

Moderna Inc. stock surged 128.72% to $144.00 on August 19, 2026, marking one of the most significant one-day gains in its history. The move was driven by positive Phase 3 trial results for a personalized mRNA cancer vaccine combination with Merck's KEYTRUDA, showing statistically significant improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. The data, released by Moderna and Merck, triggered a sharp reversal in market sentiment and wiped out nearly $4.8 billion in short-seller profits.

What Happened

The stock opened with a 57.8% gap up at $99.32, following the prior close of $62.96. By midday, shares reached an intraday high of $163.47 before retreating to close near $144.00. The session saw 87.1 million shares traded, more than 12 times the 3-month average. The news of the successful trial, which tested a low-dose Wegovy and personalized mRNA therapy, was widely reported and contributed to the stock’s momentum. RBC Capital raised its price target for Moderna to $130 from $45, while analysts at Maxim noted the data could positively impact Sellas Life Sciences ahead of its own readout. The CEO of Moderna, Stephane Bancel, had sold shares earlier in August, while a recent congressional trade by Rep. Ro Khanna (D) showed a new purchase of $1,001, $15,000 in the stock.

What The Data Shows

The stock’s fundamentals remain weak, with a trailing twelve-month net margin of -141.4% and a revenue decline of 27.6% year to date. However, the recent rally pushed the stock to a new 52-week high of $144.00, far above its previous peak of $85.60. The session’s volume and price action suggest strong institutional and retail participation, with unusual options activity showing $101.8 million in call premiums versus $41.9 million in puts. The 52-week tape also showed 32 fresh 52-week highs on the day. Despite the positive momentum, insider transactions over the past 90 days have shown only sales, totaling $35.7 million.

What To Watch

Moderna has no scheduled earnings in the immediate future, but investors will closely monitor the breadth of analyst coverage and any further developments in the cancer vaccine trial. With the stock now at a new high, the next key event will be the broader market reaction to the Phase 3 results and potential regulatory pathways for the therapy.